We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNSF.L Regulatory News (NSF)

  • There is currently no data for NSF

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proposed Recapitalisation & Directorate Change 

18 May 2023 07:00

RNS Number : 7975Z
Non-Standard Finance PLC
18 May 2023
 

Non-Standard Finance plc

('Non-Standard Finance', 'NSF' or the 'Company')

Update on proposed recapitalisation ('Proposed Recapitalisation') and Directorate Change

(18 May 2023): Further to its announcement dated 17 March 2023 regarding the launch of the Scheme and Proposed Recapitalisation or Alternative Transaction (the "17 March RNS") and its announcement dated 14 April 2023 providing an update on the Proposed Recapitalisation, the Board of Non-Standard Finance announces that Alchemy, the Group's largest shareholder, has informed the Company that it is no longer willing, in the current environment, to participate in the equity raise under the Proposed Recapitalisation on the previously notified proposed terms. The Group continues to press ahead with the Scheme and both the Proposed Recapitalisation and the Alternative Transaction, but if the Scheme is successful, the Board now feels that the Alternative Transaction is a more likely outcome than the Proposed Recapitalisation.

The Alternative Transaction will involve the transfer of the Group's business to the secured lenders in exchange for the release of a portion of their secured debt and the provision of a new lending facility. Part of the proceeds from this new lending facility would be used to fund the Scheme Fund and cover the costs of the Scheme.

Both the Alternative Transaction and the Proposed Recapitalisation will secure the future of the Everyday Loans business and allow it to pursue its growth plans providing an invaluable service for its customers. However, the Proposed Recapitalisation will materially dilute the interests of NSF's existing shareholders, most likely to negligible value, unless they choose to participate in the equity raise, and the Alternative Transaction will unfortunately result in no recovery for NSF's shareholders. The Board is continuing to consider a range of options for the NSF plc ultimate parent company in the event the Alternative Transaction is implemented, but the most likely outcome is an orderly winddown following implementation of the Alternative Transaction. In the event that the Scheme is not sanctioned by the Court, or the Scheme is sanctioned but the Proposed Recapitalisation and the Alternative Transaction both fail, then the Group would remain insolvent and the most likely outcome would be a Group-wide insolvency (most likely administration), also resulting in no return for current shareholders.

Following the communication from Alchemy regarding its position, Toby Westcott, the Alchemy nominee non-executive director of the Company, has stepped down as a director of the Company with immediate effect.

Unless otherwise defined, capitalised terms within this announcement shall have the same meaning as those contained within the 17 March RNS.

This announcement contains inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. The person responsible for arranging the release of this announcement on behalf of Non-Standard Finance plc is Sarah Day, Chief ESG Officer and Group Company Secretary.

For more information:

Non-Standard Finance plc

+44 203 869 9020

Jono Gillespie, Group Chief Executive Officer

Sarah Day, Chief ESG Officer and Company Secretary

Cenkos Securities plc 

+44 207 397 8900

Nicholas Wells

Ben Jeynes

Callum Davidson

H/Advisors Maitland

+44 207 379 5151

Neil Bennett

+44 7900 000777

Finlay Donaldson

+44 7341 788066

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSFIFAWEDSEEI
Date   Source Headline
10th Jul 20237:00 amRNSNotice of Delisting
7th Jul 20238:06 amRNSSuspension of Trading in Ordinary Shares
5th Jul 20233:18 pmRNSUpdate on Delisting and Suspension of Shares
23rd Jun 20232:51 pmRNSFiling of Annual General Meeting Resolutions
23rd Jun 20232:49 pmRNSResult of AGM
23rd Jun 20237:00 amRNSUpdate on Scheme, Delisting & Directorate Change
23rd May 20237:00 amRNSStandard form for notification of major holdings
18th May 20237:00 amRNSProposed Recapitalisation & Directorate Change 
28th Apr 20235:51 pmRNSReplacement: Update on scheme of arrangement
28th Apr 20233:33 pmRNSUpdate on scheme of arrangement
28th Apr 20238:21 amRNSAudited full year results to 31 December 2022
14th Apr 20237:00 amRNSProposed Release of Debt and Directorate Change
4th Apr 20234:14 pmRNSDirector/PDMR Shareholding
29th Mar 20234:35 pmRNSPrice Monitoring Extension
23rd Mar 20234:35 pmRNSPrice Monitoring Extension
17th Mar 20237:39 amRNSLaunch of Scheme & Proposed Recapitalisation
17th Mar 20237:00 amRNSScheme of Launch & Proposed Recapitalisation
13th Feb 20237:00 amRNS2022 Trading Statement
4th Jan 202310:15 amRNSDirector/PDMR Shareholding
3rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
3rd Jan 20234:35 pmRNSPrice Monitoring Extension
4th Oct 20224:40 pmRNSSecond Price Monitoring Extn
4th Oct 20224:35 pmRNSPrice Monitoring Extension
29th Sep 20225:50 pmRNSDirector/PDMR Shareholding
29th Sep 20224:40 pmRNSSecond Price Monitoring Extn
29th Sep 20224:37 pmRNSPrice Monitoring Extension
28th Sep 20227:05 amRNSUpdate on Current Status and Regulatory matters
28th Sep 20227:05 amRNSUnaudited Half Year Results to 30 June 2022
27th Jul 20224:41 pmRNSSecond Price Monitoring Extn
27th Jul 20224:36 pmRNSPrice Monitoring Extension
22nd Jul 20224:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20224:35 pmRNSPrice Monitoring Extension
19th Jul 20224:41 pmRNSSecond Price Monitoring Extn
19th Jul 20224:35 pmRNSPrice Monitoring Extension
6th Jul 20224:40 pmRNSSecond Price Monitoring Extn
6th Jul 20224:36 pmRNSPrice Monitoring Extension
4th Jul 20224:16 pmRNSDirector/PDMR Shareholding
15th Jun 20223:25 pmRNSFunding facilities update
26th May 20224:42 pmRNSFilings of AGM Resolutions
26th May 20222:49 pmRNSResults of Annual General Meeting
29th Apr 202212:00 pmRNSDirectorate Change
29th Apr 20227:00 amRNSAudited full year results to 31 December 2021
29th Apr 20227:00 amRNSAudited full year results to 31 December 2021
1st Apr 20224:40 pmRNSSecond Price Monitoring Extn
1st Apr 20224:35 pmRNSPrice Monitoring Extension
29th Mar 20229:26 amRNSDirector/PDMR Shareholding
17th Mar 20224:41 pmRNSSecond Price Monitoring Extn
17th Mar 20224:36 pmRNSPrice Monitoring Extension
16th Mar 20224:41 pmRNSSecond Price Monitoring Extn
16th Mar 20224:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.